AU2007244824A1 - Hepatitis C virus infection biomarkers - Google Patents

Hepatitis C virus infection biomarkers Download PDF

Info

Publication number
AU2007244824A1
AU2007244824A1 AU2007244824A AU2007244824A AU2007244824A1 AU 2007244824 A1 AU2007244824 A1 AU 2007244824A1 AU 2007244824 A AU2007244824 A AU 2007244824A AU 2007244824 A AU2007244824 A AU 2007244824A AU 2007244824 A1 AU2007244824 A1 AU 2007244824A1
Authority
AU
Australia
Prior art keywords
activity
binding
subject
protein
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007244824A
Other languages
English (en)
Inventor
Raj Bandaru
Martyn C. Botfield
Paul R. Caron
Catharine N. Cornell
Matthew W. Harding
Brian J. Hare
Kevin M. Kelliher
Ravi K. Ramachandran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of AU2007244824A1 publication Critical patent/AU2007244824A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2545/00—Reactions characterised by their quantitative nature
    • C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
    • C12Q2545/114—Reactions characterised by their quantitative nature the purpose being quantitative analysis involving a quantitation step

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007244824A 2006-04-26 2007-04-25 Hepatitis C virus infection biomarkers Abandoned AU2007244824A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79552006P 2006-04-26 2006-04-26
US60/795,520 2006-04-26
PCT/US2007/067421 WO2007127801A2 (en) 2006-04-26 2007-04-25 Hepatitis c virus infection biomarkers

Publications (1)

Publication Number Publication Date
AU2007244824A1 true AU2007244824A1 (en) 2007-11-08

Family

ID=38656353

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007244824A Abandoned AU2007244824A1 (en) 2006-04-26 2007-04-25 Hepatitis C virus infection biomarkers

Country Status (13)

Country Link
US (1) US20100028874A1 (enExample)
EP (1) EP2016195A4 (enExample)
JP (1) JP2009535036A (enExample)
KR (1) KR20090023360A (enExample)
CN (1) CN101479389A (enExample)
AU (1) AU2007244824A1 (enExample)
CA (1) CA2650616A1 (enExample)
IL (1) IL194920A0 (enExample)
MX (1) MX2008013796A (enExample)
NO (1) NO20084954L (enExample)
NZ (1) NZ573052A (enExample)
RU (1) RU2008146518A (enExample)
WO (1) WO2007127801A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
JP2009178057A (ja) * 2008-01-29 2009-08-13 Miyazakiken Sangyo Shien Zaidan インターフェロンとリバビリンとの併用治療効果の検出方法および検出キット
KR20110074870A (ko) * 2008-09-24 2011-07-04 버텍스 파마슈티칼스 인코포레이티드 간염을 치료하기 위한 ｐｅｇ-인터페론, 리바비린 및 ｖｘ-950을 포함하는 치료 요법
WO2011132086A2 (en) 2010-04-21 2011-10-27 MeMed Diagnostics, Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
CN102178927A (zh) * 2011-03-01 2011-09-14 中国人民解放军军事医学科学院放射与辐射医学研究所 干扰素诱导跨膜蛋白3在制备抗乙型肝炎病毒感染药物中的用途
CN102323426A (zh) * 2011-08-08 2012-01-18 中国人民解放军军事医学科学院放射与辐射医学研究所 用于诊断或筛查丙型肝炎病毒感染的试剂
AU2013217935B2 (en) 2012-02-09 2018-05-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CA2948803A1 (en) * 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
RU2730836C2 (ru) 2014-08-14 2020-08-26 Мемед Диагностикс Лтд. Вычислительный анализ биологических данных с применением многообразия и гиперплоскости
CN115054687A (zh) * 2014-08-22 2022-09-16 广州英恩迈生物医药科技有限公司 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
EP3230740B1 (en) 2014-12-11 2025-05-21 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof
CA3015046A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
WO2017149547A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Analyzing rna for diagnosing infection type
US11274345B2 (en) 2016-06-07 2022-03-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of bacterial and viral infections
WO2018011796A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
WO2018011795A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018060999A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CN108379584B (zh) * 2018-04-12 2020-08-11 上海交复生物医药科技有限公司 RSAD2通过wnt通路影响肿瘤细胞替莫唑胺耐药性
CN110448548B (zh) * 2018-05-08 2023-05-05 四川大学华西医院 Ifitm2抑制剂在制备治疗乙型肝炎的药物中的用途
KR102289533B1 (ko) * 2019-08-19 2021-08-17 주식회사 테라젠바이오 특정 약물의 타겟 유전자와 관련된 시그니처를 기초로 타겟 유전자와 관련된 유전자들을 판단하는 전자 장치, 방법 및 상기 방법을 실행하기 위한 컴퓨터 프로그램
CN111333710B (zh) * 2020-03-04 2021-12-03 暨南大学 C20orf24蛋白缺失突变体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517960A (ja) * 2003-02-18 2006-08-03 ファイザー インコーポレイテッド Ｃ型肝炎ウイルスの阻害剤、それを使用する組成物および治療法
US20050282179A1 (en) * 2003-12-05 2005-12-22 Applera Corporation Biomarkers for interferon-alpha response in hepatitis C virus infected patients
US7892735B2 (en) * 2004-12-30 2011-02-22 University Of Louisville Research Foundation, Inc. Genetic markers of schizophrenia spectrum disorders in the sulfotransferase 4a (sult4a) gene

Also Published As

Publication number Publication date
WO2007127801A2 (en) 2007-11-08
KR20090023360A (ko) 2009-03-04
CN101479389A (zh) 2009-07-08
NO20084954L (no) 2009-01-22
JP2009535036A (ja) 2009-10-01
EP2016195A4 (en) 2010-03-10
WO2007127801A3 (en) 2008-09-12
MX2008013796A (es) 2009-03-31
IL194920A0 (en) 2009-08-03
NZ573052A (en) 2012-03-30
RU2008146518A (ru) 2010-06-10
EP2016195A2 (en) 2009-01-21
CA2650616A1 (en) 2007-11-08
US20100028874A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
US20100028874A1 (en) Hepatitis c virus infection biomarkers
Meissner et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome
EP2115169B1 (en) Methods for determining drug sensitivity in patients infected with hcv
Manry et al. Deciphering the genetic control of gene expression following Mycobacterium leprae antigen stimulation
US20130059749A1 (en) Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy
JP2007529714A (ja) 遺伝子分析のための方法
US20110117563A1 (en) Antiviral therapy
US10072296B2 (en) Compositions and methods for sjögren's syndrome
CA3200256A1 (en) Methods and systems of stratifying inflammatory disease patients
JP7855586B2 (ja) コロナウイルス感染症を発症するリスクが高い対象を特定する方法及びその治療法
CN115066505A (zh) 生物标记物及其在治疗慢性乙型肝炎感染中的用途
JP2023055222A (ja) クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー
Macartney et al. Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure
KR102101807B1 (ko) 인슐린 저항성 진단용 조성물 및 이의 용도
US20090047245A1 (en) Prognostic chronic hepatitis C biomarkers
Jain Personalized therapy of infectious diseases
WO2018107388A1 (en) Human genetic markers associated with response to treatments that target clostridium difficile toxin b
HK1130843A (en) Hepatitis c virus infection biomarkers
Benish et al. Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations
Toyoda et al. Characteristics and outcomes of HCV genotype-1-infected patients treated with peginterferon and ribavirin combination therapy with discordant HCV responses 4 and 12 weeks after starting therapy
CN117363799A (zh) 用于预测干扰素药物治疗慢性乙型肝炎效果的组合物、产品及系统
EP4058595A1 (en) Methods for using low-dose colchicine after myocardial infarction
Ansari et al. Interferon lambda 4 impacts broadly on hepatitis C virus diversity
Fassnacht Molecular Mechanisms Involved Involved in the Interaction Effects of HCV and Ethanol on Liver Cirrhosis
Morgun et al. UltraRapid Communication

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application